BioAge Labs (BIOA) Short term Debt (2023 - 2026)

BioAge Labs has disclosed Short term Debt across 4 years of filings, most recently posting $1.2 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $1.2 million, down 80.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 80.68% YoY), and the FY2025 annual result was $2.6 million, down 55.87% from the prior year.
• Short term Debt came in at $1.2 million for Q1 2026 at BioAge Labs, down from $2.6 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $6.0 million in Q4 2023 to a low of $1.2 million in Q1 2026.
• The 4-year median for Short term Debt is $5.8 million (2023), against an average of $4.7 million.
• Across the five-year window, Short term Debt changed 0.0% in 2024 and tumbled 80.68% in 2026, its largest moves.
• BioAge Labs' Short term Debt stood at $6.0 million in 2023, then changed by 0.0% to $6.0 million in 2024, then slumped by 55.87% to $2.6 million in 2025, then plunged by 56.23% to $1.2 million in 2026.
• The last three Short term Debt figures came in at $1.2 million (Q1 2026), $2.6 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.